Pharmacology, Toxicology and Pharmaceutical Science
5 Hydroxyindoleacetic Acid
5%
Acromegaly
7%
Adverse Event
14%
Angiopeptin
13%
Antiemetic Agent
9%
Cancer of Unknown Primary Site
16%
Carcinoid
41%
Carcinoid Syndrome
68%
Chemotherapy
19%
Cimetidine
8%
Cisplatin
8%
Clinical Study
12%
Clinical Trial
13%
Colorectal Carcinoma
5%
Cyclophosphamide
8%
Debrisoquine
8%
Diarrhea
37%
Diseases
26%
Doxorubicin
5%
Everolimus
9%
Gastroenteropancreatic Neuroendocrine Tumor
16%
Immune Checkpoint Inhibitor
11%
Immunotherapy
9%
Indium 111
23%
Leporidae
12%
Malignant Neoplasm
34%
Mammalian Target of Rapamycin Inhibitor
5%
Neoplasm
24%
Neuroendocrine Tumor
94%
Octreotide
74%
Pentetreotide
21%
Pentetreotide in 111
9%
Pharmacokinetics
13%
Placebo
19%
Polyethylene Terephthalate
5%
Propranolol
8%
Radioisotope
14%
Radiosensitizing Agent
6%
Ranitidine
8%
Receptor
12%
Side Effect
7%
Solid Malignant Neoplasm
8%
Somatostatin
18%
Somatostatin Derivative
51%
Somatostatin Receptor
13%
Telotristat Ethyl
33%
Tolerability
11%
Tryptophan Hydroxylase
5%
Yttrium 90
6%
Zofran
8%
Medicine and Dentistry
5 Hydroxyindoleacetic Acid
5%
Amino Acid
7%
Cancer
18%
Cancer of Unknown Primary Origin
12%
Cancer Registry
6%
Cancer Treatment
6%
Carcinoid
48%
Carcinoid Syndrome
32%
Clinical Trial
7%
Cytoreductive Surgery
9%
Diarrhea
29%
Diseases
19%
Drug Megadose
8%
Gallium 68
8%
Gastroenteropancreatic Neuroendocrine Tumor
11%
Gastrointestinal Distress
8%
Immune Checkpoint Inhibitor
15%
Immunotherapy
5%
In Vitro
6%
Indium 111
22%
Large Cell Neuroendocrine Carcinoma
16%
Malignant Neoplasm
26%
Metastatic Carcinoma
7%
Neoplasm
27%
Neuroendocrine Carcinoma
10%
Neuroendocrine Tumor
100%
Octreotide
18%
Oncology
12%
Pancreas Adenocarcinoma
8%
Pancreas Islet Cell Tumor
12%
Pedialyte
5%
Pentetreotide
20%
Pentetreotide in 111
5%
Placebo
5%
Positron Emission Tomography-Computed Tomography
8%
Primary Tumor
5%
Quality of Life
9%
Radiation Therapy
23%
Radiopharmaceutical
6%
Solid Malignant Neoplasm
8%
Somatostatin
7%
Somatostatin Derivative
32%
Somatostatin Receptor
14%
Standardized Uptake Value
8%
Supportive Care
9%
Survival Rate
5%
Telotristat Ethyl
8%
Treatment Option
9%
Tumor
28%
X-Ray Computed Tomography
6%